» Articles » PMID: 33448693

Tissue Xanthine Oxidoreductase Activity in a Mouse Model of Aristolochic Acid Nephropathy

Overview
Journal FEBS Open Bio
Specialty Biology
Date 2021 Jan 15
PMID 33448693
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Xanthine oxidoreductase (XOR) is a critical enzyme in purine metabolism and uric acid production, and its levels are reported to increase during stress, thereby promoting organ damage. Herein, we investigated the activity of XOR in a mouse model of aristolochic acid I (AA)-induced nephropathy, a type of nephrotoxic chronic kidney disease (CKD). A persistent decrease in renal function was observed in mice up to 4 weeks after 4 weeks of AA (2.5 mg kg ) administration. Renal histology revealed an increase in tubular interstitial fibrosis over time. Although AA administration did not change XOR activity in the plasma, heart, liver, or muscle, XOR activity was persistently increased in renal tissue. Our results suggest that the renal tissue-specific increase in XOR activity is involved in the progression of tubulo-interstitial disorders, specifically fibrosis.

Citing Articles

Allopurinol, Febuxostat, and Nonuse of Xanthine Oxidoreductase Inhibitor Treatment in Patients Receiving Hemodialysis: A Longitudinal Analysis.

Ishii T, Seya N, Taguri M, Wakui H, Yoshimura A, Tamura K Kidney Med. 2024; 6(11):100896.

PMID: 39347518 PMC: 11437761. DOI: 10.1016/j.xkme.2024.100896.


Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy.

Taguchi S, Azushima K, Yamaji T, Urate S, Suzuki T, Abe E Sci Rep. 2021; 11(1):23587.

PMID: 34880315 PMC: 8654826. DOI: 10.1038/s41598-021-02864-1.

References
1.
Yisireyili M, Hayashi M, Wu H, Uchida Y, Yamamoto K, Kikuchi R . Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice. Sci Rep. 2017; 7(1):1266. PMC: 5430858. DOI: 10.1038/s41598-017-01366-3. View

2.
Page S, Powell D, Benboubetra M, Stevens C, Blake D, Selase F . Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta. 1998; 1381(2):191-202. DOI: 10.1016/s0304-4165(98)00028-2. View

3.
Hille R, Nishino T . Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. FASEB J. 1995; 9(11):995-1003. View

4.
Ives A, Nomura J, Martinon F, Roger T, Leroy D, Miner J . Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation. Nat Commun. 2015; 6:6555. PMC: 4382995. DOI: 10.1038/ncomms7555. View

5.
Gilbertson E, Krishnasamy R, Foote C, Kennard A, Jardine M, Gray N . Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review. Am J Kidney Dis. 2018; 73(3):332-343. DOI: 10.1053/j.ajkd.2018.09.006. View